NovaDigm Therapeutics

Release Summary

NovaDigm Therapeutics, today announced positive data from the Company’s Phase 2a clinical trial evaluating its NDV-3A immunotherapeutic vaccine in women with recurrent vulvovaginal candidiasis (RVVC).

NovaDigm Therapeutics